Relevant bibliographies by topics / Wen hua yan jiu

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Wen hua yan jiu'

Author: Grafiati
Published: 4 June 2021
Last updated: 27 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Wen hua yan jiu.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Wen hua yan jiu"

1

Fang, Li-Zhi. "Jiang Xiaoyuan ;, Wu Yan . Zijin shan tian wen tai shi gao: Zhongguo tian wen xue xian dai hua ge an. [History of Purplemountain Observatory.] (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 219 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2004. 29 (paper)." Isis 99, no. 3 (September 2008): 645–46. http://dx.doi.org/10.1086/593267.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wu, Song-Yang, Xi Jin, Yin Liu, Wen-Jia Zuo, Li Chen, Xiyu Liu, Lei Fan, et al. "Abstract PO1-14-07: Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial)." Cancer Research 84, no. 9_Supplement (May 2, 2024): PO1–14–07—PO1–14–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-14-07.

Full text
Abstract:
Abstract Background: Immune checkpoint inhibitors (ICIs) have heralded a new era in breast cancer treatment; however, response rates remain limited, making precision immune-oncology a major unmet need. In addition to T cells, effective immune responses to ICIs rely on coordinated interactions between innate and adaptive immune cells. Mast cells are evolutionarily conserved, tissue-resident cells of importance to human health. Specific subsets of mast cells might be endowed with opposite roles in cancer treatment, yet the extent of mast cell heterogeneity and its clinical merit in immunotherapy remain undefined. Objective: We sought to comprehensively characterize mast cells in breast cancer, investigate their association with immunotherapy response with in-depth mechanistic insights, and identify actionable strategies to modulate mast cell functional states, thereby optimizing immunotherapy efficacy. Methods: We employed single-cell profiling on longitudinal breast cancer samples from three independent clinical trials (NCT04613674, NCT03197389 and GSE169246) to delineate mast cell heterogeneity in anti-PD-(L)1 therapy. By integrating multi-omic analyses, tissue characterization, preclinical experiments, transgenic mice, and high-throughput drug screening, we outlined the molecular features, underlying mechanisms, and clinical relevance of distinct mast cells to elicit ICI-responsive microenvironments. Subsequently, we launched RENAISSANCE (NCT05076682), a proof-of-concept, Bayesian adaptive, phase 2 platform trial, to evaluate the efficacy and safety of combining mast cell therapeutics with anti-PD-1 backbone therapy in metastatic triple-negative breast cancer (TNBC) patients who progressed after immunotherapy. The primary endpoint was the objective response rate (ORR) assessed using RECIST v1.1 criteria. Results: We identified a distinct population of mast cells termed antigen-presenting mast cells (APMCs), constituting approximately 30% of intratumoral mast cells and correlating with improved clinical benefit of anti-PD-(L)1 therapy in TNBC. APMCs displayed MHC-II and costimulatory molecules, and indicated the presence of tumor-reactive T cells and tertiary lymphoid structures. Using three immunocompetent mouse models, we confirmed the immunomodulatory capacity of APMCs in immunotherapy. Mechanistically, by employing Cpa3CreERT2Cd74fl/fl mice, we demonstrated that APMCs potentiate anti-PD-1 efficacy and antitumor T cell immunity through their antigen-presentation machinery. Interestingly, we identified cromolyn, an FDA-approved drug for allergy, as a potential therapeutic agent that elicited APMC-dependent CD8+ T cell cytotoxicity to synergize with anti-PD-1 therapy. Between February 2022 and March 2023, 10 patients with immunotherapy-refractory metastatic TNBC were enrolled to receive cromolyn plus camrelizumab backbone treatment. Given Bayesian predictive probability, this arm was “graduated” due to meeting the pre-specified efficacy boundary, with an ORR of 40.0% (4/10). The treatment was well tolerated with similar safety profiles of relevant drugs. Conclusions: Our findings provide crucial insights into the impact of mast cell heterogeneity on the clinical response to ICIs at a single-cell level, and pave the way for APMC-directed therapeutic interventions in cancer treatment. To our knowledge, this is the first prospective study in breast cancer of cromolyn plus anti-PD-1 backbone regimen after anti-PD-(L)1 immunotherapy failure, demonstrating significant antitumor activity and commendable tolerability. Consequently, we suggest a phase 3 randomized study to consolidate this finding, which might be an effective treatment in patients for whom there are few effective treatment options. Citation Format: Song-Yang Wu, Xi Jin, Yin Liu, Wen-Jia Zuo, Li Chen, Xiyu Liu, Lei Fan, Zhong-Hua Wang, Yan-Fei Liu, Yi-Zhou Jiang, Zhi-Ming Shao. Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial) [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-14-07.
APA, Harvard, Vancouver, ISO, and other styles
3

Mai, Hai-Qiang, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, et al. "Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT226. http://dx.doi.org/10.1158/1538-7445.am2022-ct226.

Full text
Abstract:
Abstract Background: Gemcitabine-Cisplatin (GP) chemotherapy is the standard first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab, a humanized IgG4K monoclonal antibody specific for PD-1, in combination with GP chemotherapy showed significant improvement in progression-free survival (PFS) as first-line treatment for RM-NPC at the interim analysis of the JUPITER-02 study (NCT03581786), a randomized, placebo-controlled, double-blinded international Phase III trial. Here we report the results of the final PFS analysis and the interim overall survival (OS) analysis. Methods: Patients (n=289) with advanced NPC with no prior chemotherapy in the recurrent or metastatic setting were randomized (1:1) to receive toripalimab 240 mg (n=146) or placebo (n=143) in combination with gemcitabine and cisplatin every 3 weeks (Q3W) for up to 6 cycles, followed by monotherapy with toripalimab or placebo Q3W until disease progression, intolerable toxicity, or completion of 2 years of treatment. Stratification factors were ECOG PS (0 vs. 1) and extent of disease (recurrent vs. primary metastatic) at enrollment. Tumor response was assessed by a blinded independent review committee (BIRC) per RECIST v1.1. The primary endpoint was PFS by BIRC in the intention-to-treat population. Secondary end points included PFS by investigator, OS, objective response rate (ORR), duration of response (DOR) and safety. Results: At the final PFS analysis, the median follow-up time was 22.1 months for the toripalimab arm and 21.4 months for the placebo arm by the cut-off date of June 8, 2021. The toripalimab arm had a significantly longer PFS than the placebo arm as assessed by BIRC: median PFS 21.4 vs. 8.2 months, HR=0.52 (95% CI: 0.37-0.73), two-sided p<0.0001. The 1-year PFS rates were 59.0% vs. 32.9%. The ORR was 78.8% vs. 67.1% (P=0.022) and the median DOR was 18.0 vs. 6.0 months, HR= 0.49 (95% CI: 0.33-0.72). Consistently, PFS as assessed by investigator was also significantly longer in the toripalimab arm than the placebo arm: median PFS 17.3 vs. 8.1 months, HR=0.43 (95% CI: 0.31-0.58), P<0.0001. As of June 8, 2021, the median OS was not reached in either arm, with a trend favoring the toripalimab arm, HR=0.59 (95% CI: 0.37-0.94), P=0.024. The improvements of PFS and OS in the toripalimab arm were observed across key subgroups, including PD-L1 expression subgroups. Notably, dynamic decrease of plasma Epstein-Barr Virus DNA copy number from baseline was associated with favorable response. No new safety signal was identified. The incidence of Grade ≥3 adverse events (AEs) (89.7% vs 90.2%) and fatal AEs (2.7% vs 2.8%) were similar between the two arms; however, investigator-determined immune-related AEs (irAEs) (53.4% vs. 21.7%) and Grade ≥3 irAEs (8.9% vs. 1.4%) were more frequent in the toripalimab arm. Conclusions: The addition of toripalimab to GP chemotherapy as first-line treatment for advanced NPC had a manageable safety profile and provided superior PFS with a favorable trend in overall survival than chemotherapy alone. Citation Format: Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Yingrui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim, Rui-Hua Xu, Coherus Biosciences and Shanghai Junshi Biosciences. Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT226.
APA, Harvard, Vancouver, ISO, and other styles
4

Gao, Yue, Chun-Jie Liu, Hua-Yi Li, Xiao-Ming Xiong, Sjors G. j. g. In ‘t Veld, Gui-Ling Li, Jia-Hao Liu, et al. "Abstract LB168: Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study." Cancer Research 82, no. 12_Supplement (June 15, 2022): LB168. http://dx.doi.org/10.1158/1538-7445.am2022-lb168.

Full text
Abstract:
Abstract Background: Morpho-physiological alternations of platelets provided a rationale to harness RNA sequencing of tumor-educated platelets (TEPs) for preoperative diagnosis of cancer. Timely, accurate, and non-invasive detection of ovarian cancer in women with adnexal masses presents a significant clinical challenge. Patients and Methods: This intercontinental, hospital-based, diagnostic study included 761 treatment-naïve inpatients with histologically confirmed adnexal masses and 167 healthy controls from nine medical centers (China, n=3; Netherlands, n=5; Poland, n=1) between September 2016 and May 2019. The main outcomes were the performance of TEPs and their combination with CA125 in two Chinese (VC1 and VC2) and the European (VC3) validation cohorts collectively and independently. Exploratory outcome was the value of TEPs in public pan-cancer platelet transcriptome datasets. Results: The AUCs for TEPs in the combined validation cohort, VC1, VC2, and VC3 were 0.918 (95% CI 0.889-0.948), 0.923 (0.855-0.990), 0.918 (0.872-0.963), and 0.887 (0.813-0.960), respectively. Combination of TEPs and CA125 demonstrated an AUC of 0.922 (0.889-0.955) in the combined validation cohort; 0.955 (0.912-0.997) in VC1; 0.939 (0.901-0.977) in VC2; 0.917 (0.824-1.000) in VC3. For subgroup analysis, TEPs exhibited an AUC of 0.858, 0.859, and 0.920 to detect early-stage, borderline, non-epithelial diseases and 0.899 to discriminate ovarian cancer from endometriosis. Analysis of public datasets suggested that TEPs had potential to detect multiple malignancies (Table 1). Conclusions: TEPs had robustness, compatibility, and universality for preoperative diagnosis of ovarian cancer since it withstood validations in populations of different ethnicities, heterogeneous histological subtypes, early-stage ovarian cancer as well as other malignancies. However, these observations warrant prospective validations in a larger population before clinical utilities. Table 1. Performance for TEPs in public pan-cancer datasets. Disease n Healthy Control AUC, area under the curve (95% CI) Women NSCLC (non-small-cell lung cancer) 126 77 0.758 (0.691-0.825) Breast cancer 38 77 0.817 (0.726-0.909) Colorectal cancer 18 77 0.973 (0.945-1.000) Pancreatic cancer 16 77 0.993 (0.981-1.000) Glioblastoma 10 77 0.923 (0.831-1.000) Men NSCLC 119 82 0.746 (0.677-0.815) Colorectal cancer 25 82 0.933 (0.884-0.982) Pancreatic cancer 22 82 0.993 (0.984-1.000) Glioblastoma 19 82 0.981 (0.959-1.000) All NSCLC 245 159 0.774 (0.728-0.820) Colorectal cancer 40 159 0.978 (0.961-0.996) Breast cancer 38 159 0.821 (0.736-0.906) Pancreatic cancer 35 159 0.987 (0.974-0.999) Glioblastoma 35 159 0.931 (0.890-0.972) Hepatobiliary carcinomas 14 159 0.991 (0.978-1.000) Citation Format: Yue Gao, Chun-Jie Liu, Hua-Yi Li, Xiao-Ming Xiong, Sjors G.j.g. In ‘t Veld, Gui-Ling Li, Jia-Hao Liu, Guang-Yao Cai, Gui-Yan Xie, Shao-Qing Zeng, Yuan Wu, Jian-Hua Chi, Qiong Zhang, Xiao-Fei Jiao, Lin-Li Shi, Wan-Rong Lu, Wei-Guo Lv, Xing-Sheng Yang, Jurgen M.j. Piek, Cornelis D de Kroon, C.a.r. Lok, Anna Supernat, Sylwia Łapińska-Szumczyk, Anna Łojkowska, Anna J. Żaczek, Jacek Jassem, Bakhos A. Tannous, Nik Sol, Edward Post, Myron G. Best, Bei-Hua Kong, Xing Xie, Ding Ma, Thomas Wurdinger, An-Yuan Guo, Qing-Lei Gao. Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB168.
APA, Harvard, Vancouver, ISO, and other styles
5

Kobzev, Artem. "The Scientific Status of Oriental Studies and the Fate of Russian Sinology." Problemy dalnego vostoka, no. 6 (2021): 77. http://dx.doi.org/10.31857/s013128120017473-1.

Full text
Abstract:
The objective duality of the world, man and mankind should correspond to the pairing of Oriental studies and Western studies, however, science and pedagogy know only the first, or orientalistics. This monopoly was the result of the formation of the modern system of sciences in the field of the global domination of the West, representing the East as its opposite — the Non-West and / or interpreting interaction with it in value-asymmetric categories of culture and barbarism. The publication in 2006 of the Russian translation of E. Said's famous anti-Eastern book “Orientalism” and the scientific and educational reform of 2010-2013, provoked a discussion of Russian orientalists in the sense of the concepts of the East and the scientific status of Oriental studies as a complex and supra-branch discipline, which is either a syncretic underscience, or a synthetic superscience. Similar problems have been discussed in Russian Sinology since the 19th, since of all the highly developed cultures of the East, Chinese is the most syncretic, and the science about it is the most synthetic. In traditional China, there were no divisions customary for the West into philosophy and religion / theologians, philosophy and science, humanitarian and natural disciplines, fine and applied arts, etc. Russian Sinology, created at the beginning of the 18th century, corresponded to this specificity, simultaneously with “cutting a window to Europe” to address similar government requests. In the USSR, it was divided into classical Sinology, which was concentrated in Leningrad, with an emphasis on philology and wen-yan, and Soviet Sinology, which was concentrated in Moscow, with an emphasis on history, social studies, and bai-hua. As a result, it was possible to find the most complete reflection in accordance with the standards of classical sinology of the 6-volume encyclopedia “Spiritual Culture of China” (2006-2010). The results of this convergence were also recorded by the 10-volume “History of China from Ancient Times to the Beginning of the 21st Century”, which largely inherited Soviet Sinology (2013-2017). After analyzing these historical phenomena, the article describes the main achievements and problems of Russian Sinology over the past decade and the challenges it faces in the light of the modern rethinking of the scientific status of all oriental studies.
APA, Harvard, Vancouver, ISO, and other styles
6

He, Yan, Zhenyu Luo, Yiyao Wang, Shan Xiong, Rui Wan, Xue Zhang, Hua Bai, and Jie Wang. "Abstract 5426: SMC2 orchestrates non-small cell lung cancer proliferation, invasion, and metastasis by modulating the ERK/AKT/NF-κB pathways." Cancer Research 84, no. 6_Supplement (March 22, 2024): 5426. http://dx.doi.org/10.1158/1538-7445.am2024-5426.

Full text
Abstract:
Abstract Chromatin instability has been associated with the expression of structural maintenance of chromosomes (SMC) family members and is a common feature in many tumors. SMC family members have been associated with poor outcomes in several cancer types. However, little is known about their functions and mechanisms in promoting cancer progression, particularly in non-small cell lung cancer (NSCLC). Here, we evaluated the expression of SMC family members in the tumor microenvironment of NSCLC specimens using single-cell RNA sequencing analyses. After a survival analysis, it was found that the sole factor associated with a poor prognosis for NSCLC was member SMC2 expression. Immunohistochemistry was used with data from the Human Protein Atlas, the Cancer Genome Atlas, and the Gene Expression Omnibus databases to confirm the overexpression of SMC2 in NSCLC. We demonstrated that SMC2 regulates not only the fluctuations in the critical states of tumor cells, which are defined by different transcriptome and metabolic properties but also coordinates the immunological components and cell-to-cell communications of the immune milieu, potentially through the pleiotrophin and the Galectin pathways. In vitro and in vivo evidence support the pro-metastatic role of SMC2 in NSCLC. Subsequent investigations showed that SMC2 increases NSCLC progression and metastasis via modulating the ERK/AKT/NF-κB pathway and the epithelial-mesenchymal transition process. Our research clarifies the role and potential mechanisms of SMC2 in NSCLC, providing new treatment options and valuable insights for the management of NSCLC. Citation Format: Yan He, Zhenyu Luo, Yiyao Wang, Shan Xiong, Rui Wan, Xue Zhang, Hua Bai, Jie Wang. SMC2 orchestrates non-small cell lung cancer proliferation, invasion, and metastasis by modulating the ERK/AKT/NF-κB pathways [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5426.
APA, Harvard, Vancouver, ISO, and other styles
7

Lv, Hong, Qian-Ming Bai, Yin Liu, Zhong-Hua Wang, Ruo-Hong Shui, Hong-Fen Lu, Xiao-Li Xu, et al. "Abstract P2-13-11: Response to anti-HER2 neoadjuvant chemotherapy in invasive breast cancers with different HER2 FISH-positive patterns." Cancer Research 82, no. 4_Supplement (February 15, 2022): P2–13–11—P2–13–11. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-13-11.

Full text
Abstract:
Abstract Backgrounds: Since human epidermal growth factor receptor 2 (HER2)-positive breast cancers may have different HER2/CEP17 ratios and HER2 copy numbers, outcomes of HER2-positive breast cancer patients treated with anti-HER2 neoadjuvant chemotherapy (NACT) may be different. The aim of this study is to explore the relationship between different groups of HER2 fluorescence in situ hybridization (FISH) positive patterns and response to anti-HER2 NACT. Methods: 513 HER2-positive invasive breast cancers who received anti-HER2 NACT in Fudan University Shanghai Cancer Center, during January 2015 to September 2020, were collected. According to FISH results, 513 patients were divided into three groups. Group A: HER2/CEP17 < 2.0 and HER2 average copy number ≥6.0; Group B: HER2/CEP17≥2.0 and HER2 average copy number ≥4.0 and < 6.0; Group C: HER2/CEP17≥2.0 and HER2 average copy number ≥6.0. Clinicopathological characteristics and pathological complete response(pCR) rates of three groups were analyzed. Results: All 513 patients were treated with anti-HER2 NACT. The anti-HER2 treatment included trastuzumab in 463 (90.3%) patients, trastuzumab plus pertuzumab in 21 (4.1%) patients, trastuzumab plus lapatinib in 3 (0.6%) patients, and trastuzumab plus pyrotinib in 1 (0.2%) patient. 25 (4.9%) cases were unblinded in clinical trials, who were treated either with trastuzumab plus pertuzumab or with trastuzumab plus pyrotinib. Among 513 patients, 237 cases (46.2%)were luminal B (hormone receptor positive and HER2 positive) and 276 cases (53.8%) were hormone receptor negative and HER2 overexpressed (HER2 overexpression type). According to IHC results, cases with HER2 1+,2+ and 3+ were 8 (1.6%), 123 (24.0%) and 382(74.5%), respectively. Among them, 0.0%, 25.2%, and 48.7% achieved pCR (p<0.001). The pCR rate of HER2 overexpression type was higher than that of luminal B type (54.0% vs 28.7%, P<0.001). Lymph nodes with metastasis after NACT in luminal B type was higher than that of HER2 overexpression type (43.0% vs 21.4%, P<0.001). According to HER2-FISH results, 11 cases (2.1%) were group A, 28 cases (5.5%) were group B and 474 cases (92.4%) were group C. Compared with the pCR rate of group A (36.4%) and group C (44.5%), the pCR rate in group B (7.1%) was significantly lower (p<0.001). Conclusions: Among HER2-positive breast cancers, HER2 protein expression level was positively correlated with pCR rate. Luminal B(HER2+)patients benefited less from anti-HER2 NACT than HER2 overexpression patients. Although all were invasive breast cancers with positive HER2-FISH results, patients with HER2/CEP17≥2.0 and HER2 copy number ≥4.0 and <6.0 seemed to respond less favorably to anti-HER2 NACT compared with other groups. The biological characteristics of this group of patients are worthy of further study. Citation Format: Hong Lv, Qian-Ming Bai, Yin Liu, Zhong-Hua Wang, Ruo-Hong Shui, Hong-Fen Lu, Xiao-Li Xu, Bao-Hua Yu, Xiao-Yu Tu, Rui Bi, Yu-Fan Cheng, Xiao-Yan Zhou, Zhi-Min Shao, Wen-Tao Yang. Response to anti-HER2 neoadjuvant chemotherapy in invasive breast cancers with different HER2 FISH-positive patterns [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-11.
APA, Harvard, Vancouver, ISO, and other styles
8

Chung, Juliette Yuehtsen. "Bo Liang. Ji shu yu di guo yi yan jiu: riben zai Zhongguo de zhi min ke yan ji gou [Researches on Technology and Imperialism: Japanese Colonial Scientific Research Institutes in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 345 pp., figs., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2006. ¥38 (paper).Jianping Han;, Xingsui Cao;, Liwei Wu. Ri wei shi qi de zhi min di ke yan ji gou: li shi yu wen xian [Colonial Scientific Institutions during the Japanese Occupation and Puppet Manchukuo Period: History and Literature]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 468 pp., figs., bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2006. ¥49 (paper)." Isis 99, no. 2 (June 2008): 429–30. http://dx.doi.org/10.1086/591369.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

He, Yan, Zhenyu Luo, Yucheng Dong, Rui Wan, Xue Zhang, Hua Bai, and Jie Wang. "Abstract 4139: Prolyl 4-hydroxylase subunit alpha 1 acts as a novel target for lung adenocarcinoma brain metastasis." Cancer Research 84, no. 6_Supplement (March 22, 2024): 4139. http://dx.doi.org/10.1158/1538-7445.am2024-4139.

Full text
Abstract:
Abstract Lung cancer is the most lethal cancer worldwide, with a high incidence of distant metastasis. Many lung adenocarcinoma (LUAD) patients experience brain metastasis during the disease process with unfavorable prognosis. Our previous study has discovered that P4HA1 was exclusively upregulated in brain metastatic cells. Through the analysis of single-cell RNA sequencing of LUAD samples, we found that the expression of P4HA1 in brain metastatic tumor cells is higher than that in primary tumor cells. This finding was further confirmed by immunohistochemical staining. Significantly, a strong presence of P4HA1 in primary tumors is associated with a reduced duration of disease-free survival in individuals with LUAD. Overexpression of P4HA1 in A549 and PC9 cell lines significantly increased the incidence of brain metastasis in BALB/c nude mice, whereas knockdown of P4HA1 in high brain metastatic cells significantly decreased the incidence of brain metastasis and reduced the tumor foci in brain with improved survival. Utilization of DHB, a P4HA1 inhibitor, exerts both therapeutic and preventive effects in relieving brain metastases in nude mice. Furthermore, remarkable inhibition of tumor growth by DHB was observed in patient derived xenograft (PDX) models. RNA sequencing analysis demonstrated that the reduction of P4HA1 expression had a substantial impact on cell adhesion and extracellular matrix (ECM)-receptors interactions. Western blotting analysis verified that the decrease in P4HA1 expression led to a drop in the expression of adhesion molecules ICAM1, VCAM1, NCAM1, as well as integrin molecules ITGA2 and ITGA3. Furthermore, when endothelial cells were co-cultured with conditioned medium from tumor cells, it was observed that the expression of the tight junction molecule ZO1 was reduced after co-culturing with conditioned medium from P4HA1 knockdown A549 cells. The results from the in vitro blood-brain barrier (BBB) model and in vivo biofluorescence imaging indicate that P4HA1 promoted brain metastasis of LUAD via modulating the ability of tumor cells to cross the blood-brain barrier. In conclusion, our study reveals that overexpression of P4HA1 promotes metastatic spread to the brain, and targeting P4HA1 could be a promising therapeutic strategy for the treatment of lung adenocarcinoma brain metastasis. Citation Format: Yan He, Zhenyu Luo, Yucheng Dong, Rui Wan, Xue Zhang, Hua Bai, Jie Wang. Prolyl 4-hydroxylase subunit alpha 1 acts as a novel target for lung adenocarcinoma brain metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4139.
APA, Harvard, Vancouver, ISO, and other styles
10

羅秀美, 羅秀美. "文化記憶的追尋與再現：以「故宮文學家」作品中的「北溝故宮」書寫為主." 中正漢學研究 34, no. 34 (December 2019): 149–84. http://dx.doi.org/10.53106/2306036020191200340006.

Full text
Abstract:
<p>1949年後北京故宮輾轉播遷至臺灣，落腳於臺中霧峰北溝(1950-1965)十六年。守護者莊嚴全家也落腳於此，此地乃當時臺中最重要的文化及旅遊勝地。然1965年北溝故宮北遷後，空餘庫房山洞供人憑弔。當時曾出現一批「故宮文學家」，他們與「北溝故宮」有或深或淺的關係，曾留下相關記憶的書寫，這些文本正是本論文考察的對象。職是，本論文以文化空間與文學記憶為論述概念，首論偏安北溝的「回憶空間」，莊嚴父子大半生與故宮文物流離至北溝所構建的回憶空間。其次則論在此文化空間的文人對傳統文化的傳承，即孔德成與臺靜農等人至北溝故宮清點文物的記憶。第三則論及個體記憶的再現，以臺靜農與林文月、凌叔華與蘇雪林的北溝旅行為主。第四則論及集體記憶中的文化旅遊勝地，兼論齊邦媛的英譯暨陪訪史。透過以上討論，可在集體的歷史大敘述外，呈現個體的文學記憶，豐富北溝故宮之文化記憶。</p> <p>&nbsp;</p><p>After 1949, the Palace Museum from Beijing relocated to Taiwan and settled in Beigou北溝 of Taichung (1950-1965) for 16 years. Zhuang Yan莊嚴 and his family who guard the Palace Museum in Beigou北溝故宮 is also setteled here, this place also was the most important cultural tourist attraction in Taichung.However, after the Palace Museum in Beigou北溝故宮 moved northward in 1965, the empty warehouse caves in this area were for people to hang. At that time, a group of &quot; the Palace Museum writers故宮文學家&quot; appeared. They had a deep or shallow relationship with the &quot; the Palace Museum in Beigou北溝故宮&quot;,they had left relevant memory writing,these texts are the objects of this paper. In this paper, the concept of cultural space and literary memory is discussed in this dissertation. Firstly, discussion is about the &ldquo;memory space&rdquo; in Beigou北溝,the memory space constructed by the Zhuang Yan莊嚴 father and son for most of his life and the Palace Museum 故宮’s cultural relics moved to Beigou北溝. Secondly, it discusses the inheritance of traditional culture by the literati in this cultural space, that is, the memory of Kung Te-Cheng孔德成 and Tai Jing-nong臺靜農 and others to the Palace Museum in Beigou北溝故宮 to count the cultural relics. Thirdly, on the reappearance of personal memory, mainly on the the Palace Museum in Beigou北溝故宮 trip of Tai Jing-nong臺靜農 and Lin Wen-yue林文月, Ling Shu-hua凌叔華and Su Xue-lin蘇雪林. Fourthly, the cultural tourism resort in the collective memory, as well as the history of Qi Bang-yuan’s齊邦媛English translation and accompanying visits. Through the above-mentioned discussion, the individual’s literary memory can be presented in addition to the collective grand historical narrative, especially enrich the cultural memory of the Palace Museum in Beigou北溝故宮.</p> <p>&nbsp;</p>
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Wen hua yan jiu"

1

Li, Siya. "Hu Yinglin wen xue si xiang yan jiu /." View abstract or full-text, 2008. http://library.ust.hk/cgi/db/thesis.pl?HUMA%202008%20LIS.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hsu, King Chiu. ""Shui hu zhuan" wen ben ping gai yan jiu /." View abstract or full-text, 2005. http://library.ust.hk/cgi/db/thesis.pl?HUMA%202005%20HSU.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wu, Hanxiao, and 吳晗瀟. "Chinese teachers' authority in cross culture classrooms = Zhong wen jiao shi zai kua wen hua jiao xue zhong dui jiao shi quan wei de li jie he tai du de yan jiu." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/209678.

Full text
Abstract:
本文主要探討了中文二語教師在跨文化教學中對教師權威的理解和態度。東西方文化的差異在教師權威方面的表現，是彼此對師生間權力距離的認同並不一樣，東方文化中，權力距離較大，教師更為權威；而西方文化則權力距離較小，學生擁有更多的自由。本研究採訪了香港某國際學校的9名中外二語教師，得出結論：中文二語教師還是重視尊師重道的傳統，但對於教師權威已有了與時俱進的理解，面對外國學生,師生互相協商、尊重，從而達到課堂的學習目標才是教師權威的真正意義。受訪者採取1）樹立嚴師形象、運用獎懲機制；2）從學生角度考慮，尊重、幫助學生；3）自我提升，贏得學生尊重的方式，來應對學生挑戰教師權威的行為。影響受訪者形成如上教師權威的理解和態度，并選擇用以上的方式應對學生挑戰教師權威行為的策略，因素为：成長環境和教學經驗；獎懲制度和職位的肯定；個人性格、師生關係；以及網絡時代的挑戰；教師需要通過不斷進修、學習來提升自我。 本文通過分析跨文化教學中，中文教師的教師權威的理解和態度，應對策略和影響因素，引出思考和啓發：1）教師權威需要被重視和理論化；2）教師權威應在跨文化教學中因應學生的需要而轉變；3）區別對待中外學生的原因在于用不同的方法，達到公平、一視同仁的結果，希望學生的需要得到重視和照顧；4）學校教育與社會的關係意味著教師權威被理論化的重要性；5）當代教育學者應著手將教師權威理論化，從而也能使中文二語教師在跨文化教學中有據可循，重建教師權威。
published_or_final_version
Education
Master
Master of Education
APA, Harvard, Vancouver, ISO, and other styles
4

Tan, Jianbin. "Gu gu tou que xue xing huai si de zhong yi yao zhi liao wen xian yan jiu /." click here to view the abstract and table of contents, 2006. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b20009343a.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wu, Tsz Wing. "Li Yu gai bian ju yan jiu : jian lun wen ren chuan qi yu shi min wen xue zhi rong he /." View abstract or full-text, 2006. http://library.ust.hk/cgi/db/thesis.pl?HUMA%202006%20WU.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chow, Wai-chun. "On the relationship between the prose and comics of Feng Zikai Feng Zikai san wen yu man hua chuang zuo guan xi yan jiu /." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B40717380.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lou, Chi-kuan. "A study of Europeanized linguistic features in the writings of Lu Xun (1881-1936) = Lu Xun (1881-1936) ou hua wen zi yan jiu /." Hong Kong : University of Hong Kong, 2002. http://sunzi.lib.hku.hk/hkuto/record.jsp?B25100609.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

廖麗暉 and Lai-fai Liu. "Chinese temple and Chinese community in colonial Hong Kong : a case study of Man Mo Temple in Sheung Wan = Hua ren miao yu yu zhi min di de Xianggang Hua ren she hui : yi Shanghuan Wen wu miao wei yan jiu ge an." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/192998.

Full text
Abstract:
The Man Mo Temple（文武廟）Compound on Hollywood Road, Sheung Wan, which comprises three blocks, namely Man Mo Temple, Lit Shing Kung （列聖宮） and Kung Sor（公所）, were built in 1847 . The Temple was built mainly for the worship of Man Cheong (God of Literature, 文昌) and Mo Tai (God of Martial Arts, 武帝). It was important assembly hall where Chinese people discussed issues and resolved disputes in early colonial period. The Temple represented the traditional social organization and religious practices of the Chinese community in the past. The aim of this study examines the development of Man Mon Temple from 1840s to 1908. This thesis contains six main chapters. The first chapter is literature review of previous researches for Man Mo Temple, as well as presents the objectives and methodology of the thesis. The second chapter explores the reasons for its establishment. The third chapter describes the development of architecture of temple. The forth chapter describes and analyses the Guandi worship （關帝信仰）and Wenchang belief （文昌信仰）in Hong Kong. The fifth chapter evaluates the significance of Man Mo Temple on different periods. The temple provided religious service, also as sponsor the charitable work of the Chinese community. It analyses the change of the temple’s function in colonial period. The final chapter is a conclusion how the Man Mo Temple shift to accommodate changing needs of the colonial development.
published_or_final_version
Chinese Historical Studies
Master
Master of Arts
APA, Harvard, Vancouver, ISO, and other styles
9

Luo, Yin. ""Kong", "you" yu "you", "wu" : xuan xue yu bi re xue jiao hui wen ti zhi yan jiu /." Tai Bei : Guo li Tai Wan da xue, 2003. http://catalogue.bnf.fr/ark:/12148/cb39291212m.

Full text
Abstract:
Th. doct.--Philosophie--Taibei--National Taiwan University = Guo li Tai Wan da xue, 2000.
Mention parallèle de titre ou de responsabilité : "Sunyata", "Dravysati" & "yo", "wo" : ontological research for the combination of Chinese metaphysic and Indian Prajna philosophy in A.D.300-500. Bibliogr. p. 385-399.
APA, Harvard, Vancouver, ISO, and other styles
10

Chiu, Man-yee Angela. "Striking the buddhist chord in snowy regions contemporary Chinese poetry on Tibetan culture = Qiao xiang xue yu de fan yin : Zhongguo dang dai Zang wen hua Han yu xin shi yan jiu /." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B41385251.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Wen hua yan jiu"

1

Tao wen hua yan jiu: Tao wen hua yan jiu. Beijing: Zhongguo dang an chu ban she, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yao wen hua yan jiu. Kunming Shi: Yunnan ren min chu ban she, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yan wen hua yan jiu. Baoding Shi: Hebei da xue chu ban she, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1947-, Guo Qiyong, ed. Ru jia wen hua yan jiu. Beijing Shi: Sheng huo, du shu, xin zhi san lian shu dian, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Guying, Chen, ed. Dao jia wen hua yan jiu. Taibei Shi: Wen shi zhe chu ban she, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1947-, Guo Qiyong, ed. Ru jia wen hua yan jiu. Beijing Shi: Sheng huo, du shu, xin zhi san lian shu dian, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Guying, Chen, and Xianggang dao jiao xue yuan., eds. Dao jia wen hua yan jiu. Shanghai: Shanghai gu ji chu ban she, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhou, Yixin. Shiwan yao wen hua yan jiu. Guangzhou: Zhongshan da xue chu ban she, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lanling jiu wen hua yan jiu. Jinan: Shandong ren min chu ban she, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Guang, Chen, ed. Yan wen hua yan jiu lun wen ji. Beijing: Zhongguo she hui ke xue chu ban she, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Wen hua yan jiu"

1

Taber, Douglass F. "The Tan/Chen/Yang Synthesis of Schindilactone A." In Organic Synthesis. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780190200794.003.0088.

Full text
Abstract:
Schindilactone A 3 is one of a closely related family of polycyclic lactones that have been used in China for the treatment of rheumatic disease. The synthesis of 3 reported (Angew. Chem. Int. Ed. 2011, 50, 7373) by Ye-Feng Tang of Tsinghua University and Jia-Hua Chen and Zhen Yang of Peking University is an elegant tour of metal-mediated bond construction, as exemplified by the cyclization of 1 to 2. The preparation of 1 began with the Diels-Alder reaction of 4 with the butadiene 5. Addition of methyl magnesium chloride converted 6 to the crystalline lactone 7. Angular hydroxylation followed by ring expansion gave the bromo enone 8, which was homologated to the lactone 11. Apparently, the bulky silyloxy group directed the addition of the butenyl Grignard reagent 10 to the top face of the ketone carbonyl. Hydroxylation of the lactone followed by the addition of 12 then gave 1 as a mixture of diastereomers. Only one of the two diastereomers of 1 could undergo ring-closing metathesis to form the second of the three carbocyclic rings of 3. The two lactol diastereomers were in equilibrium with each other by way of the open-chain enone. When MgBr2 was added to encourage equilibration, the metathesis proceeded to completion to give 2. The tertiary alcohol of 2 was esterified with 2-butynoic acid to give 13. Intramolecular Pauson-Khand cyclization, using the optimized protocol developed by the authors, then delivered the enone 13, completing the last carbocyclic ring of 3. The last remarkable metal-mediated reaction in the synthesis was the oxidative carbonylation of 14 to 15. It is not clear if the postcarbonylation event is direct Pd-mediated C–O bond formation or the intramolecular addition of alkoxide to a transient butenolide. To complete the synthesis, 15 was methylated, then deprotonated and kinetically quenched to set the proper relative configuration of the last methyl group. Remarkably, despite the presence in the molecule of three other acidic protons, including the one that had just been removed and kinetically reset, exposure of the acetate 16 to a large excess of base, followed by oxidation, gave clean conversion to schindilactone A 3.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Wen hua yan jiu"

1

"Hua Zhang Zheng Yuan Qiao-yan Wen." In 2007 IFIP International Conference on Network and Parallel Computing Workshops (NPC 2007). IEEE, 2007. http://dx.doi.org/10.1109/npc.2007.78.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Wen hua yan jiu' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography